Singapore approves Pfizer’s oral COVID-19 medicine Paxlovid

Paxlovid, a Pfizer’s coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS /File Photo

SINGAPORE, Feb 3 (Reuters) – Singapore has approved Pfizer’s (PFE.N) oral COVID-19 medicine Paxlovid, its Health Sciences Authority (HSA) said on Thursday.

Paxlovid is the first COVID-19 oral treatment authorised for use in the city-state for the treatment of mild to moderate cases among adults at high risk of severe disease, HSA said in a statement.

Reporting by Chen Lin; Editing by Martin Petty

Our Standards: The Thomson Reuters Trust Principles.